{"nctId":"NCT02347332","briefTitle":"Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer","startDateStruct":{"date":"2014-04-25","type":"ACTUAL"},"conditions":["Recurrent or Metastatic Head and Neck Carcinoma"],"count":459,"armGroups":[{"label":"Vinflunine plus methotrexate","type":"EXPERIMENTAL","interventionNames":["Drug: Vinflunine"]},{"label":"Methotrexate","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Methotrexate"]}],"interventions":[{"name":"Vinflunine","otherNames":["JAVLOR","VFL"]},{"name":"Methotrexate","otherNames":["MTX"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed recurrent and/or metastatic squamous cell carcinoma\n* Documented progressive disease after chemotherapy for locoregionally advanced or recurrent/metastatic SCCHN which included a platinum derivative\n* Measurable or non measurable disease\n* adequate haematological, hepatic and renal functions\n* WHO performance status \\< 1\n\nExclusion Criteria:\n\n* Nasopharyngeal carcinoma\n* History of brain or leptomeningeal involvement\n* Albumin level \\< 35 g/L\n* Patients with weight loss â‰¥ 5% within the last 3 months\n* Grade \\> 2 peripheral neuropathy at study entry\n* \"Third space\" fluids (pleural effusion, ascites, massive edema)\n* Prior treatment with vinca-alkaloids and methotrexate","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival in the ITT Population (Months)","description":"Time from randomization to the date of death or last follow-up. The survival duration of patients still alive, was censored at the date of last contact or last follow-up.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":null},{"groupId":"OG001","value":"6.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival","description":"Time measured from the date of randomisation until date of progression or death from any cause (whichever came first)","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":null},{"groupId":"OG001","value":"2.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR)","description":"The objective response is defined as the best response designation recorded across all time points from the date of randomisation until disease progression.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.8","spread":null},{"groupId":"OG001","value":"14.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease Control Rate","description":"Percentage of best overall responses CR, PR and SD in the analysed population","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.9","spread":null},{"groupId":"OG001","value":"46.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response","description":"Duration of objective response will be measured for responders (CR+PR) from the time for CR or PR until the 1st date of documentation of recurrent or progressive disease or the date of death any cause.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":null},{"groupId":"OG001","value":"4.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":106,"n":225},"commonTop":["Neutropenia","Anaemia","Weight decreased","Stomatitis","Asthenia"]}}}